28 September 2017 (Thursday) - The Oncologist E-newsletter

The Oncologist e-newsletter arrived today. One or two snippets, but the thing was incredibly clinically biased. I suppose it would be, wouldn’t it?

Featured Article The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy Kyriaki Tzogani et al. Carfilzomib (Kyprolis) was approved in the European Union in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The addition of carfilzomib to lenalidomide and dexamethasone resulted in a clinically meaningful and statistically significant improvement of progression‐free survival compared with lenalidomide and dexamethasone, which was supported by a clear trend in overall survival benefit, although the data were not mature. At the time of the marketing authorization of carfilzomib, the delay in disease progression appeared superior to available alternatives in the setting of relapsed multiple myeloma. In terms of safety, the overall accepted safety profile was considered manageable. In the News Focus Screening Efforts to 'Save Thousands of Lives' from Digestive Cancers -- Say Experts How Big a Threat to Cancer Research Is Brexit? Cancer Immunotherapy Proves Itself in Earlier-Stage Disease

CME Activities Oncofertility: Fertile Ground for Conflict Between Patient Autonomy and Medical Values Neutrophil-Lymphocyte Ratio (NLR) Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA & IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy ADVERTISEMENT

Clinical Trial Results A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia Lesson Learned > Ofatumumab infusion reactions can be diminished by escalating the dose rate in individual patients in sequential infusions.